18 May 2026
GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59
Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.
